Barbara J. Klencke, M.D.
Barbara J. Klencke, M.D. is a world-class drug developer and research & development expert, having made significant contributions to the oncology community with the development and approval of several first-in-class therapies. Since 2015, she has served as the chief medical officer of Sierra Oncology Inc., a publicly traded clinical-stage biopharmaceutical company recently acquired by GSK in 2022. From 2011 to 2015, Barbara served as senior vice president of global development at Onyx Pharmaceuticals, acquired by Amgen Inc. in 2013. She also led a variety of both early- and late-stage oncology programs while at Genentech, Inc. from 2003 to 2011. Barbara currently serves as a member of the Board of Directors of eFFECTOR Therapeutics.
Barbara received her M.D. from the University of California, Davis (UC Davis) and completed her internal medicine residency and hematology/oncology fellowship at the University of California, San Francisco (UCSF) and remained at UCSF as an assistant professor of medicine in oncology focusing on clinical research from 1995 – 2002.